https://scholars.lib.ntu.edu.tw/handle/123456789/551087
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | CHEN-HUA LIU | en_US |
dc.contributor.author | CHUN-JEN LIU | en_US |
dc.contributor.author | TUNG-HUNG SU | en_US |
dc.contributor.author | YU-JEN FANG | en_US |
dc.contributor.author | HUNG-CHIH YANG | en_US |
dc.contributor.author | PEI-JER CHEN | en_US |
dc.contributor.author | DING-SHINN CHEN | en_US |
dc.contributor.author | JIA-HORNG KAO | en_US |
dc.date.accessioned | 2021-03-09T01:43:25Z | - |
dc.date.available | 2021-03-09T01:43:25Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 2328-8957 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85028857012&doi=10.1093%2fOFID%2fOFX028&partnerID=40&md5=ab94f822ff83c6d034b6d949197fb457 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/551087 | - |
dc.description.abstract | Background. Little is known about the risk of hepatitis B virus (HBV) reactivation in patients receiving interferon (IFN)-free direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV). Methods. Patients who were seropositive for HBV core antibody and who received IFN-free DAAs for HCV were enrolled. Hepatitis B virus reactivation was defined as reappearance of serum HBV deoxyribonucleic acid (DNA) ?100 IU/mL in patients with baseline undetectable viral load, or ?2 log10 IU/mL increase of HBV DNA in patients with baseline detectable viral load. Hepatitis B virus-related alanine aminotransferase (ALT) flare was defined as ALT ?5 times upper limit of normal or ?2 times of the baseline level. Hepatitis B virus-related hepatic decompensation was defined as presence of jaundice, coagulopathy, hepatic encephalopathy, or ascites. Results. Compared with no HBV reactivation in 81 HBV surface antigen (HBsAg)-negative patients, 2 of 12 HBsAg-positive patients had HBV reactivation (0% [confidence interval (95% CI), 0%-4.5%] vs 16.7% [95% CI, 4.7%-44.8%], P = .015). No patients had ALT flare or hepatic decompensation. Baseline HBsAg level at a cutoff value of 500 IU/mL was associated with HBV reactivation in HBsAg-positive patients. There was no HBsAg seroreversion in HBsAg-negative patients. Conclusions. Hepatitis B virus reactivation is limited to HBsAg-positive patients receiving IFN-free DAAs for HCV. Higher baseline HBsAg levels are associated with HBV reactivation. The risk of ALT flares or hepatic decompensation is low in these patients. ? The Authors 2017. | en_US |
dc.publisher | Oxford University Press | en_US |
dc.relation.ispartof | Open Forum Infectious Diseases | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | alanine aminotransferase; antivirus agent; bilirubin; dasabuvir plus ombitasvir plus paritaprevir plus ritonavir; hemoglobin; hepatitis B surface antigen; ledipasvir; peginterferon; ribavirin; sofosbuvir; virus DNA; virus RNA; adult; aged; antiviral therapy; Article; bacterial peritonitis; chronic hepatitis C; cohort analysis; decompensated liver cirrhosis; female; Hepatitis B virus; Hepatitis C virus; Hepatitis C virus genotype 2; Hepatitis C virus subtype 1a; Hepatitis C virus subtype 1b; human; major clinical study; male; priority journal; prospective study; risk assessment; viremia; virus load; virus reactivation | - |
dc.title | Hepatitis B virus reactivation in patients receiving interferon-free direct-acting antiviral agents for chronic hepatitis C virus infection | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1093/OFID/OFX028 | - |
dc.identifier.scopus | 2-s2.0-85028857012 | - |
dc.relation.journalvolume | 4 | en_US |
dc.relation.journalissue | 1 | en_US |
item.cerifentitytype | Publications | - |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUHYL | - |
crisitem.author.dept | Microbiology | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.orcid | 0000-0003-3622-9707 | - |
crisitem.author.orcid | 0000-0002-6202-0993 | - |
crisitem.author.orcid | 0000-0002-6747-7941 | - |
crisitem.author.orcid | 0000-0003-3864-9895 | - |
crisitem.author.orcid | 0000-0001-8316-3785 | - |
crisitem.author.orcid | 0000-0001-7791-6154 | - |
crisitem.author.orcid | 0000-0002-2442-7952 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital Yun-Lin Branch | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。